CSBR
Champions Oncology, Inc.
CSBR lost money over the past year, so it has no meaningful PE right now.
CSBR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Strong |
CSBR's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
CSBR PE Valuation
CSBR has no meaningful PE right now: it lost money over the past year.
CSBR Forward outlook
There aren't enough analyst estimates for CSBR to show an outlook.
CSBR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.08 | -138% |
| Q2 2026 | -$0.08 | -124% |
| Q1 2026 | -$0.15 | -134% |
| Q4 2025 | $0.18 | +$0.24 |
| Q3 2025 | $0.21 | +$0.47 |
| Q2 2025 | $0.33 | +$0.87 |
| Q1 2025 | $0.44 | +$1.16 |
| Q4 2024 | -$0.06 | +$0.65 |
CSBR has swung to a loss: it lost $0.08 per share over the past year, after a profit the year before.
CSBR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $15.2M | +8.8% |
| Q2 2026 | $13.8M | +12% |
| Q1 2026 | $16.6M | -2.8% |
| Q4 2025 | $15M | +11% |
| Q3 2025 | $14M | -0.5% |
| Q2 2025 | $12.4M | -12% |
| Q1 2025 | $17M | +42% |
| Q4 2024 | $13.5M | +17% |
CSBR's revenue is growing: $15M last quarter, up 8.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.7% | +1.1 points |
| Q2 2026 | -3.8% | +13 points |
| Q1 2026 | -1.7% | -28 points |
| Q4 2025 | 1.2% | -4.2 points |
| Q3 2025 | -3.8% | -13 points |
| Q2 2025 | -16% | -14 points |
| Q1 2025 | 26% | +48 points |
| Q4 2024 | 5.4% | +22 points |
CSBR's operating margin was −2.7% last quarter, up 1.1 points from the same quarter a year ago.
CSBR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$547K | -199% |
| Q2 2026 | -$2.2M | -134% |
| Q1 2026 | -$1.4M | -407% |
| Q4 2025 | -$2M | -$1.6M |
| Q3 2025 | $554K | +78% |
| Q2 2025 | $6.6M | +$8.3M |
| Q1 2025 | $448K | +$1.5M |
| Q4 2024 | -$377K | -186% |
CSBR's free cash flow was −$6M over the past year, against $7M the year before.
CSBR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +65.2K shares |
| 1 year | +0.8% | +109K shares |
| 3 years | +2.9% | +391K shares |
| 5 years | +3.7% | +496K shares |
| Available history | +7.2% | +933K shares |
CSBR has 14M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | $32,000 |
| Q3 2023 | $602,000 |
CSBR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -15.0x | Net Cash |
| Q2 2026 | -22.6x | Net Cash |
| Q4 2025 | -2.3x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -3.3x | Net Cash |
| Q4 2022 | -5.2x | Net Cash |
CSBR has more cash than debt.
CSBR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 11.5 | Oversold |
CSBR's weekly RSI is 37 (neutral) and its Stochastic is 11 (oversold).
CSBR PE vs Healthcare Sector
| Metric | CSBR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CSBR has no meaningful PE right now: it lost money over the past year.
CSBR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.79 | 2.9% below |
| 20 week MA | $5.17 | 10% below |
| 50 week MA | $5.83 | 20% below |
| 100 week MA | $6.81 | 32% below |
| 200 week MA | $6.01 | 23% below |
CSBR is in a downtrend: it's below all five of its weekly moving averages, and 23% below its 200-week average.
CSBR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.71 | $11.2 | +45% |
| 2021 | $11.2 | $8.04 | -28% |
| 2022 | $8.04 | $4.48 | -44% |
| 2023 | $4.48 | $5.62 | +25% |
| 2024 | $5.62 | $8.35 | +49% |
| 2025 | $8.35 | $6.98 | -16% |
| 2026 YTD | $6.98 | $4.65 | -33% |
CSBR has finished lower in three of the last six years. It's down 33% so far in 2026.